Objective: Perampanel (PER), a selective non-competitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist, exhibits broad-spectrum anticonvulsant activity in several seizure models, but its potential disease-modifying effects have not been investigated. Because of the relevance of AMPA receptors in epileptogenesis and psychiatric comorbidities, we studied the effects of PER in the WAG/ Rij rat model of epileptogenesis, absence epilepsy, and depressive-like comorbidity. Methods: We investigated the effects of acute, subchronic, and chronic treatment with PER (0.25-3 mg/kg) on absence seizures, their development, and related psychiatric/ neurologic comorbidity in WAG/Rij rats. Depression-related behavior was studied by using the forced swimming and the sucrose preference test; anxiety-related behavior by using the open field and elevated plus maze test; and memory by using the passive avoidance test. Results: PER (3 mg/kg/day orally for 17 weeks starting from P30) significantly reduced the development of absence seizures at 6 months of age (1 month after treatment withdrawal), but this effect was not maintained when reassessed 4 months later. Attenuated absence seizure development was accompanied by reduced depressivelike behavior in the forced swimming test (FST), whereas no effects were observed on anxiety-related behavior and memory. Subchronic (1 and 3 mg/kg/day orally for 1 week) and acute PER (0.25-1 mg/kg, i.p.) dosing did not affect established absence seizures and behavior. Significance: These results suggest that AMPA receptors are involved in mechanisms of epileptogenesis in an established model of absence epilepsy, and that these mechanisms differ from those responsible for seizure generation and spread when epilepsy has become established.
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, the main receptors involved in glutamate-mediated fast excitatory postsynaptic neurotransmission, play a crucial role in the generation and spread of epileptic activity, 2 and therefore AMPA receptors have long been considered a suitable target for antiepileptic drug (AED) development. Several structurally distinct competitive and noncompetitive AMPAreceptor antagonists show potent activity in many preclinical models of epilepsy, 2, 3 and there is evidence that these compounds can play a neuroprotective role by preventing neuronal death, and can also inhibit epileptogenesis. 3, 4 Perampanel (PER) is the first selective noncompetitive AMPA-receptor antagonist approved for the adjunctive treatment of focal seizures, with or without secondary generalization, and primarily generalized tonic-clonic seizures. 3, 5 In animal models, PER showed broad spectrum activity against audiogenic seizures in DBA/2 mice, maximal electroshock seizures, pentylenetetrazol-induced seizures, seizures associated with the 6 Hz model and in the rat amygdala kindling model of temporal lobe epilepsy, and diazepam-resistant status epilepticus in the lithium-pilocarpine rat model. 6, 7 However, to date no data have been reported on its potential disease-modifying effects, despite evidence for a role of AMPA receptors in neuroprotection and psychiatric morbidity. 3, 8 The WAG/Rij rat provides a validated model of absence epilepsy with comorbid mild depression and has gained attention as a valuable model to investigate epileptogenesis. [9] [10] [11] [12] Because of its features, this model permits evaluation at the same time potential activities against development of epilepsy as well psychiatric comorbidity. In the present study, WAG/Rij rats were used to investigate the effects of PER on the development of absence seizures, and depressive-and anxiety-like behavior. Because an age-dependent learning and memory deficit in the WAG/Rij rats has been reported, we also evaluated PER effects on cognitive function. 13, 14 Adult WAG/Rij rats were also used to test the effects of acute and subchronic PER in animals in which seizures and comorbidities had become established.
Methods

Animals
Male WAG/Rij rats (n = 156), originally purchased from Charles River Laboratories s.r.l. (Calco, Lecco, Italy) were obtained from our breeding colony at the University of Catanzaro. Animals were housed three or four per cage and kept under controlled environmental conditions (60 AE 5% humidity; 22 AE 2°C; 12/12 h reversed light/dark cycle; lights on at 20.00). Animals were allowed free access to standard laboratory chow and tap water. The study was approved by the local ethics committee, and all procedures involving animals and their care were in compliance with international and national regulations (EU Directive 2010/ 63/EU for animal experiments, Animal Research: Reporting In Vivo Experiments guidelines, and the Basel declaration including the 3R concept).
PER administration/experimental protocols
The effects of PER (Eisai s.r.l., Italy) on absence seizures and behavior were evaluated under three different treatment schedules. For more details on methods see Data S1.
Acute treatment
For acute studies, PER (0.25, 0.5 and 1 mg/kg) was freshly prepared in distilled water, dimethyl sulfoxide, and polyethylene glycol (PEG) 300 (1:1:1; v/v) and administered intraperitoneally (i.p.) to adult WAG/Rij rats (about 6 months of age; total number of rats used = 36) as a single dose. Different groups (n = 6) were utilized for each dose and test paradigm (i.e., electroencephalography [EEG] recordings and behavioral tests). A 3 mg/kg dose could not be used because it induced clear signs of sedation and ataxia. EEG effects were studied for 4 h starting immediately after administration, 10 whereas behavior was evaluated 30 min after administration. To reduce the number of animals used, for acute testing we used only the forced swimming test (FST) and the elevated plus maze (EPM) test (see Behavioral tests section).
Subchronic treatment
In these experiments, the possible antiepileptic effects of PER (1 and 3 mg/kg/day) as well as its effects on animal behavior were evaluated in adult WAG/Rij rats (about 6 months of age; total number of rats used = 36) treated for at least seven consecutive days (for multiple tests in the same group rats were kept under treatment until completion of testing). For rats also undergoing EEG recording, treatment was started 1 week after surgery for electrode implantation (see section on Animal surgery and EEG recordings).
Early long-term (chronic) treatment
In the chronic treatment experiments, PER (1 and 3 mg/ kg/day; n = 6 for each experimental group) was administered for about 17 weeks (up to the age of 5 months) starting at postnatal day 30 (P30). PER was initially solubilized in a minimal amount of ethanol, which was then diluted in the drinking water 9 to obtain a solution containing <0.5% ethanol. Tap water containing 0.5% ethanol was used as vehicle for control rats. Animals were weighed weekly every Monday between 9:00 and 11:00 a.m., and a 1 ml blood sample was obtained every month through the tail vein of three randomly selected rats of PER-treated groups for later analysis of serum PER concentrations. Animals were restrained gently during this process. Particular attention was paid to appearance of any obvious side effects. To reduce the number of animals used, the group of rats undergoing EEG recordings at 6 and 10 months of age was also used at 10 months for behavioral experiments, whereas a different group was used for the behavioral tests at 6 months ( Fig. 1 ).
Animal surgery and EEG recordings
For EEG recordings, WAG/Rij rats were chronically implanted, under anesthesia (tiletamine/zolazepam 1:1; Zoletil 100; 50 mg/kg i.p.; VIRBAC s.r.l., Milan, Italy), using a Kopf stereotaxic instrument, with five cortical electrodes. 9, 10, 15 At least 1 week recovery was allowed before EEG recordings, which were made using a multichannel amplifier (Stellate Harmonie Electroencephalograph; Montreal, QC, Canada) starting at 9.00 a.m. in order to avoid the Figure 1 . Scheme of the experimental protocol used in the study. The acute protocol is reported in red, the subchronic treatment in blue, and the early longterm chronic treatment in violet. confounding effect of circadian changes within groups. Blinded quantification of absence seizures was based on number and duration of spike-wave discharges (SWDs) in EEG recordings. 10 
Determination of serum PER concentrations
Following blood collection, the serum was separated within 1 h and stored at À20°C until assay. Serum PER concentrations were determined by using a validated high-performance liquid chromatography (HPLC) method with ultraviolet (UV) light according to Franco et al., 16 with minor modifications.
Behavioral tests
Behavioral testing included the FST, the sucrose preference test (SPT), the Open Field (OF) test, the EPM test, and the passive avoidance (PA) test. For all tests, the ETHOVision XT8 software from Noldus (The Netherlands) was used for automated analysis. Acutely treated animals underwent only FST and then EPM (n = 6 for each dose). In the subchronic treatment protocol, two subgroups (n = 18) for each dose or vehicle were randomly selected, with the first subgroup being used (in this order) to record EEG, FST, OF, and EPM, and the second subgroup being used for PA test and then SPT. In the chronically treated group, subgroups (n = 18) of animals for each dose and vehicle underwent the following tests: (1) EEG recordings at 6 and 10 months of age, followed by FST, OF, and EPM; (2) FST, OF, and EPM at 6 months of age; (3) PA test and SPT at 6 months of age; and (4) PA test and SPT at 10 months of age (Fig. 1) .
Forced swimming test (FST)
For the measurement of immobility time and assessment of depressive-like behavior in WAG/Rij rats, 9,10 rats were individually forced to swim during 6 min in a clear plastic cylinder (47 cm height; 38 cm diameter) containing 38 cm of water at 22-23°C. The total duration of immobility, including passive swimming, was measured in the last 4 min of the test. The criterion for passive swimming was floating vertically in the water while making only those movements necessary to keep the head above the water.
Sucrose preference test (SPT)
Anhedonia, a key component of depression, can be measured in rats by testing their preference to consume a sweetened solution. For the SPT, rats were individually placed in cages and habituated to a 2% sucrose solution for 48 h before the test day. Rats were water and food deprived for 4 h between 1:00 and 5:00 p.m., and this period was followed by a 1 h preference test with water and 2% sucrose delivered from identical bottles. The bottles containing water and sucrose were weighed before and after this period, and sucrose preference (%) was determined. The sum of the water plus sucrose intake was defined as the total intake, and a sucrose preference was expressed as the percentage of sucrose intake relative to the total intake.
Open field (OF) test
The OF test was performed as described previously.
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The animal was placed in the center of the field and the time spent in the center and the number of center entries were analyzed. Lower activity in the OF test is considered to represent a measure of a higher level of anxiety and vice versa. 10 The parameters measured included time spent in the center, total distance moved, and mean velocity during the 10 min test.
Elevated plus maze (EPM) test
The test was performed as described previously. 17 Briefly, the apparatus was elevated 80 cm above the floor and exposed to dim illumination (40 W). The maze consisted of two opposite open arms (50 cm 9 10 cm) and two opposite closed arms of the same size with walls 40 cm high. The arms were connected by a central square (10 cm 9 10 cm). An animal was placed in the center of the maze facing a closed arm. The number of entries into and the time spent on each arm and in the central square were scored for 10 min.
Passive avoidance (PA) PA, a well-established test to assess learning and memory, 18 was evaluated using a step-through method. The test apparatus (model 40550, Ugo Basile, Comerio, Varese, Italy) consisted of an illuminated chamber connected to a dark chamber via a guillotine door and a grid floor that could deliver an electric shock (0.3 mA for 3 s) using a shock generator. On day 1, each rat was allowed to enter the dark chamber for 90 s, and was acclimatized to the apparatus. On day 2, each rat was placed in the illuminated closed chamber; after 1 min, the door was opened and when the rats moved completely into the dark chamber, the door was closed and an electric foot shock was delivered (training sessions). In this trial, the initial latency (IL) of entrance into the dark chamber was recorded. Animals that did not step through the door within the cutoff time (300 s) were not used. The latency to move to the light from the dark in order to avoid the shock was used as an indicator of learning and memory. On day 3, the rat was again placed in the illuminated chamber and allowed to reenter the dark chamber: the retention time, defined in this session as the latency to enter the dark chamber, was measured (test sessions) with a cutoff duration of 300 s. The retention time was used as a measure of memory.
Statistical analysis
All statistical procedures were performed using the SPSS 15.0.0 software (SPSS Inc., Chicago, IL, U.S.A.). EEG recordings were divided into 30 min epochs, and the duration and number of spike-wave discharges (SWDs) were assessed separately for every epoch and averaged. Data obtained were expressed as mean AE standard error of the mean (SEM) for every dose of the test drug. Results were compared by one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test. All tests used were two sided and p ≤ 0.05 was considered significant.
Results
Effects of PER on established absence seizures and their development
Acute (0.25-1 mg/kg, i.p.) and subchronic (1 and 3 mg/ kg/day) administration of PER to adult rats did not cause any significant change in the number and total duration of SWDs in comparison with the control group (data not shown).
Chronic treatment with PER at 1 mg/kg/day up to 5 months of age was not effective in inhibiting the development of absence seizures as assessed by EEG recordings made at 6 and 10 months of age, although there was a trend for absence activity to be slightly reduced at 6 months (Fig. 2) . At the dose of 3 mg/kg/day, chronic treatment with PER was associated with a significant (p < 0.028) reduction in the development of spontaneous SWDs (both number and total duration) at 6 months of age, but this effect did not persist at the age of 10 months (5 months after treatment withdrawal) (Fig. 2) . The mean duration of individual SWDs at 6 and 10 months was not modified by PER.
Effects of PER on behavior
After acute (0.25, 0.5, and 1 mg/kg, i.p.) and subchronic (1 and 3 mg/kg/day, p.o.) administration of PER to adult rats, no significant effects were detected on both FST and SPT results (data not shown). By contrast, chronic PER treatment was associated with a significant reduction in immobility time at 6 months of age, by about 25% at 1 mg/ kg and by about 40% at 3 mg/kg (p < 0.05 at both doses, Fig. 3A ). An increased sucrose preference was also found in chronically treated rats at 6 months of age (Fig. 3B) . However, these effects were not maintained at 10 months of age (5 months after PER withdrawal), similarly to the observations made for absence seizures (Fig. 3B) .
Irrespective of dose and duration of treatment, PER was not found to affect significantly other behavioral tests, including test of anxiety-like behavior (OF and EPM) and memory function (PA) (data not shown).
Animal growth, side effects, and serum PER concentrations
Animal growth during chronic PER treatment was similar within and between groups, with no significant differences Figure 2 . Effects of chronic treatment with perampanel (PER) on spike-wave discharges (SWDs) recorded in WAG/Rij rats at 6 (6 m) and 10 (10 m) months of age. Data (means AE SEM, n = 6 per group) are expressed as percentage change relative to 6-month-old control rats (dotted line; values for control rats were: nSWDs = 7.76 AE 0.51; dSWDs = 28.9 AE 2.24; nSWDs = 3.72 AE 2.39). *Significantly different (p < 0.05) from age-matched control rats. CTRL, control rats; nSWDs, mean number of SWDs for every 30-min epoch; dSWDs, mean cumulative duration of SWDs for every 30-min epoch expressed in seconds(s); sSWD, mean duration of a single SWD expressed in (s). Epilepsia ILAE between PER-exposed and control animals during the 17-week treatment period. During the last 2 weeks of chronic treatment, at 3 mg/kg/day, four of six rats showed signs of ataxia, which disappeared within 1 week of stopping treatment.
Serum PER concentrations, monitored monthly in the chronically treated animals, remained relatively stable during the treatment period in each dose group. Average concentrations were 14.0 (standard deviation [SD] 2.7) ng/ml at the 1 mg/kg dose and 33.1 (SD 9.8) ng/ml at the 3 mg/kg dose.
Discussion
The term epileptogenesis encompasses the development or aggravation of spontaneous seizures as well as the development of related comorbidity such as cognitive decline or psychiatric disturbances. 19 Our experiments indicate that, in the WAG/Rij rat model, PER reduces the development of absences in terms of frequency and total duration, and that this effect is only temporary since at 5 months after drug withdrawal absence seizures return to the control level. Of interest, the antiepileptogenic effect recorded 1 month after drug withdrawal was associated with protection against development of depressive-like behavior, which normally accompanies the occurrence of seizures in these animals. 20 Protection against depressive-like morbidity, however, was no longer detectable 5 months after drug withdrawal, suggesting that behavioral and seizure manifestations are closely related and possibly share common underlying mechanisms. Irrespective of timing and duration of treatment, PER did not seem to affect anxiety-like behavior or memory function.
The lack of efficacy of PER against established absence seizures in the WAG/Rij rats is consistent with similar findings reported previously in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS), another rat model of absence epilepsy, 6 and with the general notion that systemically administered noncompetitive AMPA antagonists do not effectively suppress epileptic absences. 21, 22 In WAG/ Rij rats, however, noncompetitive AMPA receptor antagonists do reduce SWDs when injected into the nucleus reticularis thalami and the S1po (peri-oral region of the primary somatosensory cortex), but not when injected into the thalamus. 23 Furthermore, LY300164 (Talampanel; a noncompetitive AMPA receptor antagonist) was found to have weak activity reducing only the number but not the duration of SWDs for a very short time period and only at the highest dose of 16 mg/kg (within 1 h after administration; Effective Dose 50 = 15.5 mg/kg). 24 This discrepancy might depend on the possibility that PER and LY300164 might have different binding properties, even if both are noncompetitive antagonists, and this would also be in line with the observation that the competitive antagonist CNQX is much more potent than both noncompetitive antagonists 25 and therefore different mechanisms of receptor blockade might influence drug response. Finally, it is not possible to exclude that higher doses of PER might have had an effect; however, higher doses in this study could not be used according to the development of drug-dependent toxicity (see Acute treatment section).
The finding that PER does not affect established absence seizures but attenuated the development of absence epilepsy is intriguing, and suggests that AMPA receptors can influence epileptogenesis and seizure generation in different ways. Previous studies indicated that, at least in WAG/Rij rats, there are specific alterations in GluA2 and GluA4 subunits of AMPA receptors, which could be associated with either absence seizures and/or epileptogenesis. 23, 26 AMPA receptors modifications may be early mediators of an epileptogenic cascade and, in particular, changes in AMPA receptor phosphorylation seem to be important for (B) Effect of chronic treatment with perampanel (PER) on the results of the sucrose preference test. Data show the preference for a 20% sucrose solution in 1 h expressed in grams (g; n = 6) in WAG/Rij rats at the age of 6 months (left side) and 10 months (right side). Values are means AE SEM (n = 6). *Significantly different (p < 0.05) from age-matched control rats (CTRL). Epilepsia ILAE epileptogenesis. 4, 27, 28 Antiepileptogenic effects for PER and other AMPA receptor antagonists, such as NBQX, GYKI, and Talampanel, have also been reported with administration during the latent period immediately following neonatal hypoxic seizures, a well-known epileptogenic insult. 4, 28 It could by hypothesized that during brain development AMPA receptors are involved in plastic changes necessary to develop spontaneous seizures. By interfering with this process, PER might be able to prevent early seizures development, even though if the cause of epileptogenesis is not removed (as in a genetic model of epilepsy), seizures eventually become fully established later in life.
In our study, PER had no detrimental effect on behavioral tests, including tests for mood and memory. In clinical practice, psychiatric and behavioral disturbances are a known adverse effect in a minority of PER-treated patients, 29 and, while global cognitive scores are not altered by the drug, impairment in some cognitive domains does occur. 30 A recent investigation of the effects of an AMPA-positive allosteric modulator (PAM) and GYKI-53655, a noncompetitive antagonist, demonstrated that in rats PAMs are antidepressant in the FST and tail suspension test (TST) but increase anxiety-related behavior, whereas GYKI-53655 is pro-depressant in the TST but not in the FST and possesses anxiolytic-like effects in several tests. 8 Our results are only partly in agreement with those reported in the latter study, possibly due to differences in testing conditions (e.g., drug treatment duration, animal model, etc.). Both our study and the study by Andreasen et al. (2015) , however, confirmed that noncompetitive AMPA receptor antagonists have no major effect on memory function.
In conclusion, our results demonstrate that PER, administered for 17 weeks early during development, has antiepileptogenic effects in the WAG/Rij rat model of absence epilepsy and attenuates the development of absence seizures as well as psychiatric (depressive-like) comorbidity. However, the protective effect is only temporary, and both seizures and behavioral manifestations becomes fully established later in life. Because PER is devoid of any activity against established absence seizure, the delay in the full development of seizure activity is likely to be mediated by mechanisms different from those involved in seizure generation and spread. Further elucidation of these mechanism could lead to a better understanding of the role of AMPA receptors in epileptogenesis and seizure suppression.
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